NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc (NTI (TM)) (NASDAQ:NTII) announced today that Warren Wasiewski, M.D. was appointed Chief Medical Officer, effective as of November 26, 2007. Dr. Wasiewski joined NTI in February 2007 as Vice President, Clinical Programs with primary responsibility for running the clinical trial program for Viprinex(TM), NTI's drug candidate for acute ischemic stroke that is currently in two Phase 3 clinical trials. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTI, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate. Dr. Wasiewski holds a Bachelor of Arts degree in Biology Cum Laude from Rutgers College, a Masters of Science degree in Biochemistry from State University of New York Downstate Medical Center, and a Doctorate of Medicine from State University of New York, at Buffalo. About Neurobiological Technologies, Inc. NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Craig Carlson of Neurobiological Technologies, Inc., +1-510-595-6000,

Copyright